Coverage
-
January 12, 2022
A California federal judge granted preliminary approval of the $12.7 million settlement between Odonate Therapeutics Inc. and investors on Wednesday, ending a class action that accused the pharmaceutical company of misleading investors by concealing information on a trial for a chemotherapy agent in development.
1 other articles on this case.
View all »